
Oveporexton Approved First in China: The First OX2R Agonist Targeting the Underlying Mechanism of Type 1 Narcolepsy
Oveporexton approved first in China, becoming the world’s first approved selective orexin receptor 2 (OX2R)…

Oveporexton approved first in China, becoming the world’s first approved selective orexin receptor 2 (OX2R)…

For patients living with transfusion-dependent beta thalassemia (TDT), lifelong blood transfusions have long been the…

Izalontamab Brengitecan is the first approved ADC for esophageal squamous cell carcinoma (ESCC) worldwide. It…

Lung cancer remains the leading cause of cancer death worldwide, with non-small cell lung cancer…

On July 1, China’s National Medical Products Administration (NMPA) approved Adamgammadex Sodium Injection for marketing.…

Before the advent of targeted therapy, ALK-positive advanced non-small cell lung cancer (NSCLC) typically progressed…

On June 25, 2026, the National Medical Products Administration (NMPA) announced Octahydroaminoacridine Succinate approved in…

Ovarian cancer drugs in China mainly include five categories: PARP inhibitors, anti-angiogenic therapies, antibody-drug conjugates…

Epidermal growth factor receptor EGFR–targeted drugs represent a cornerstone in the treatment of advanced non–small…

DengYueMed is a licensed Pharmaceutical Distributor in Hong Kong providing wholesale pharmaceuticals, global drug export,…